{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+alfa-2a+%2B+Ribavirin&page=2", "query": { "intervention": "Peginterferon alfa-2a + Ribavirin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 150, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+alfa-2a+%2B+Ribavirin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+alfa-2a+%2B+Ribavirin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T11:06:51.857Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01573351", "title": "Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Asunaprevir", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Peg-interferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2012-05", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 20, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573351" }, { "nct_id": "NCT00991289", "title": "Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "Hepatitis C Infection" ], "interventions": [ { "name": "Nitazoxanide (NTZ)", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a (PEG)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2010-01", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991289" }, { "nct_id": "NCT00845676", "title": "Treatment of Acute Hepatitis C Virus in HIV Co-Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C", "Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "Pegylated interferon alfa-2a + Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2008-03", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2020-05-18", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00845676" }, { "nct_id": "NCT01415141", "title": "Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-07", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Burlington, Vermont", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01415141" }, { "nct_id": "NCT01194037", "title": "A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection", "Genotype 1" ], "interventions": [ { "name": "recombinant variant of interferon-alpha 2b", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HanAll BioPharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2011-06-23", "completion_date": "2011-11-28", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 6, "location_summary": "Los Angeles, California • National City, California • Miami, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194037" }, { "nct_id": "NCT01821963", "title": "Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection" ], "interventions": [ { "name": "Pegylated Interferon Alfa 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 1, "start_date": "2013-04", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01821963" }, { "nct_id": "NCT00747539", "title": "Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV", "Hepatitis C", "Infections" ], "interventions": [ { "name": "Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2008-07", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2016-05-13", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 4, "location_summary": "Lancaster, California • Los Angeles, California", "locations": [ { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00747539" }, { "nct_id": "NCT00275548", "title": "Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Liver Transplant", "Hepatitis C" ], "interventions": [ { "name": "Pegasys", "type": "DRUG" }, { "name": "Copegus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 12, "start_date": "2004-07", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2011-11-11", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00275548" }, { "nct_id": "NCT01471574", "title": "Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Genotype 1" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "PEG-Interferon alfa 2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 549, "start_date": "2011-12", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-01-29", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 23, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471574" }, { "nct_id": "NCT00963885", "title": "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "RO5190591 (Danoprevir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2009-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-13T11:06:51.857Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00963885" } ] }